Home » Posts tagged with » Chris Boshoff
IBRANCE fails to meet primary endpoint in early breast cancer trial

IBRANCE fails to meet primary endpoint in early breast cancer trial

Pfizer said that the phase 3 PENELOPE-B clinical trial of IBRANCE (palbociclib) in early breast cancer failed to meet its primary endpoint. The collaborative late-stage trial is being held by the US pharma giant with the German Breast Group (GBG) sponsoring it. The primary endpoint of the PENELOPE-B clinical trial is improved invasive disease-free survival […]

Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men

New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover the treatment of hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. Latest Ibrance FDA approval Under the new indication approved […]

Continue reading …
Pfizer lung cancer drug Vizimpro bags CHMP’s positive opinion

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Pfizer lung cancer drug Vizimpro (dacomitinib) 45 mg in Europe as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The positive opinion adopted by the European Medicines Agency (EMA) committee is […]

Continue reading …
Vyriad, Merck to launch phase 1 study of immuno oncology drugs Voyager-V1 and avelumab

Vyriad, a US biotech company, has entered into a collaboration with Germany-based Merck to launch a phase 1 trial of their immuno oncology drugs combination of Voyager-V1 and Bavencio (avelumab), respectively, for metastatic colorectal cancer. According to Vyriad, Voyager-V1 is an oncolytic virotherapy which is a bullet-shaped, negative-sense RNA virus having low human seroprevalence. The […]

Continue reading …